Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2022 | The evolving treatment paradigm for BRAF V600E-mutant mCRC

Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, describes the current and future treatment options for patients with microsatellite instability (MSI)-high BRAF V600E-mutant metastatic colorectal cancer (mCRC). Trials are currently underway to assess cetuximab with EFGR antibodies and the Phase III BREAKWATER trial (NCT04607421) assess encorafenib, a BRAF inhibitor, with cetuximab. Prof. Stintzing additionally highlights research elucidating mechanisms of resistance to current treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.